Sarina A Piha-Paul

Sarina A Piha-Paul

UNVERIFIED PROFILE

Are you Sarina A Piha-Paul?   Register this Author

Register author
Sarina A Piha-Paul

Sarina A Piha-Paul

Publications by authors named "Sarina A Piha-Paul"

Are you Sarina A Piha-Paul?   Register this Author

70Publications

2278Reads

45Profile Views

Vandetanib photoinduced cutaneous toxicities.

Cutis 2019 May;103(5):E24-E29

Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, and Department of Dermatology, University of Texas Medical School, Houston, USA.

View Article

Download full-text PDF

Source
May 2019

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.

JCO Clin Cancer Inform 2018 12;2:1-14

Goldy C. George, Adrianna Buford, Kenneth Hess, Sarina A. Piha-Paul, Ralph Zinner, Vivek Subbiah, Christina Hinojosa, Charles S. Cleeland, Funda Meric-Bernstam, and David S. Hong, The University of Texas MD Anderson Cancer Center; and Elmer V. Bernstam, The University of Texas School of Biomedical Informatics, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00030DOI Listing
December 2018

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Cancer Chemother Pharmacol 2018 11 4;82(5):877-885. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3680-yDOI Listing
November 2018

Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.

J Clin Oncol 2018 01 8;36(1):61-67. Epub 2017 Nov 8.

Toshihiko Doi, National Cancer Center East, Chiba, Japan; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Shadia I. Jalal, Indiana University School of Medicine, Indianapolis, IN; Sanatan Saraf, Jared Lunceford, and Minori Koshiji, Merck, Kenilworth, NJ; and Jaafar Bennouna, Institut de Cancérologie de l'Ouest, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.9846DOI Listing
January 2018

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

J Clin Oncol 2017 Dec 2;35(36):4035-4041. Epub 2017 Nov 2.

Jean-Sebastien Frenel, Institut de Cancerologie de l'Ouest, Centre René Gauducheau, Saint-Herblain; Christophe Le Tourneau, Institut Curie, Paris and Saint-Cloud, and Institut National de la Santé et de la Recherche Médicale U900 Research Unit, Saint-Cloud; Carlos Gomez-Roca, Institut Claudius Regaud, Toulouse; Andrea Varga, Gustave Roussy, Villejuif, France; Bert O'Neil, Indiana University Health University Hospital, Indianapolis, IN; Patrick A. Ott, Dana-Farber Cancer Institute, Boston, MA; Sarina A. Piha-Paul, The University of Texas MD Anderson Cancer Center, Houston, TX; Emilie M.J. van Brummelen, The Netherlands Cancer Institute, Amsterdam, Netherlands; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; and Shari Thomas, Sanatan Saraf, and Reshma Rangwala, Merck & Co., Inc., Kenilworth, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.5471DOI Listing
December 2017

Cutaneous Metastasis of a Mucoepidermoid Carcinoma of the Pancreas: First Reported Case.

Am J Dermatopathol 2016 Nov;38(11):852-856

Departments of *Investigational Cancer Therapeutics, †Pathology, and ‡Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000604DOI Listing
November 2016

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.

Clin Cancer Res 2015 Dec 17;21(23):5235-44. Epub 2015 Jul 17.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0180DOI Listing
December 2015

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.

Invest New Drugs 2015 Aug 21;33(4):911-20. Epub 2015 May 21.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-015-0251-5
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0251-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492845PMC
August 2015

A decision support framework for genomically informed investigational cancer therapy.

J Natl Cancer Inst 2015 Jul 11;107(7). Epub 2015 Apr 11.

Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy , the University of Texas MD Anderson Cancer Center, Houston, TX (FMB, AJ, VH, AMB, JZ, KRS, JM, GBM); Departments of Investigational Cancer Therapeutics (FMB, LB, SAPP, DSH, AMT), Surgical Oncology (FMB), Hematopathology (MR, KPP), Bioinformatics & Computational Biology (KC), GI Medical Oncology (SK), Melanoma Medical Oncology (MAD), Experimental Therapeutics (RB), Systems Biology (AKE, GBM), the University of Texas MD Anderson Cancer Center, Houston, TX; School of Biomedical Informatics, the University of Texas Health Science Center, Houston, TX (EVB).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/7/djv098.full.pdf
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/djv098
Publisher Site
http://dx.doi.org/10.1093/jnci/djv098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651038PMC
July 2015

Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.

Curr Pharm Biotechnol 2014 ;15(5):475-85

Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.42, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389201015666140519123219DOI Listing
May 2015

MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors.

Clin Genitourin Cancer 2015 Feb 3;13(1):e19-26. Epub 2014 Jul 3.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.06.017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144738PMC
February 2015

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Invest New Drugs 2015 Feb 18;33(1):177-86. Epub 2014 Oct 18.

Sarah Cannon Research Institute at HealthONE, Presbyterian/St. Luke's Medical Center, 1800 Williams Street, Suite 300, Denver, CO, 80218, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0173-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297242PMC
February 2015

Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.

Anticancer Res 2014 Apr;34(4):1939-45

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1500 Holcombe Boulevard, Unit 455, Houston, TX 77030, U.S.A.

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/content/34/4/1939.full.pdf
Web Search
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685166PMC
April 2014

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Mol Cancer Ther 2013 Dec 3;12(12):2857-63. Epub 2013 Oct 3.

Corresponding Author: Filip Janku, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8.2018, Box 0455, Houston, Texas 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0319-TDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158732PMC
December 2013

Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.

Mol Cancer Ther 2013 Oct 20;12(10):2167-75. Epub 2013 Aug 20.

Corresponding Author: Jennifer Wheler, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1400 Holcombe Boulevard, Houston, TX 77030.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138057PMC
October 2013

Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.

J Cancer Res Clin Oncol 2013 Jun 2;139(6):963-70. Epub 2013 Mar 2.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00432-013-1404-6
Publisher Site
http://dx.doi.org/10.1007/s00432-013-1404-6DOI Listing
June 2013

Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver.

Cancer Chemother Pharmacol 2013 Feb 11;71(2):389-97. Epub 2012 Nov 11.

Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-012-2014-8DOI Listing
February 2013

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Cancer Res 2013 Jan 12;73(1):276-84. Epub 2012 Oct 12.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537862PMC
January 2013

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Oncotarget 2012 Dec;3(12):1566-75

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681495PMC
http://dx.doi.org/10.18632/oncotarget.716DOI Listing
December 2012

The "shield sign" in two men with metastatic salivary duct carcinoma to the skin: cutaneous metastases presenting as carcinoma hemorrhagiectoides.

J Clin Aesthet Dermatol 2012 Sep;5(9):27-36

The University of Houston Health Center, University of Houston, Houston, Texas ; The Department of Dermatology, University of Texas-Houston Medical School, Houston, Texas ; The Departments of Dermatology.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460659PMC
September 2012

Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.

J Clin Oncol 2011 Sep 15;29(26):e727-30. Epub 2011 Aug 15.

Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.36.2095DOI Listing
September 2011

Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment.

J Clin Oncol 2011 Apr 24;29(12):e333-5. Epub 2011 Jan 24.

University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.32.5928DOI Listing
April 2011

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Mol Cancer Ther 2011 Mar 7;10(3):558-65. Epub 2011 Jan 7.

Department of Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., FC8.2057, Box 0455, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072168PMC
March 2011